Sotera reaffirms low end of guidance

 

• Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022
• Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income of $25 million or $0.09 per diluted share in Q3 2022
• Q3 2023 Adjusted EBITDA of $134 million increased 7%, compared to Q3 2022
• Q3 2023 Adjusted EPS of $0.21 decreased $0.02 per diluted share, compared to Q3 2022 driven by higher interest expense
• Company reaffirms 2023 outlook, anticipates results at the lower end of the range

https://www.globenewswire.com/news-release/2023/11/01/2770991/0/en/Sotera-Health-Reports-Third-Quarter-and-Year-to-Date-2023-Results.html